Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + PD-1 inhibitor + GM-CSF + tegafur/gimeracil/oteracil in recurrent/metastatic nasopharyngeal carcinoma
ChiCTR2200060662Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim and tegafur in recurrent nasopharyngeal carcinoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate, Duration of response and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
sargramostimtegafur
03
Conditions
recurrent nasopharyngeal carcinoma
Beyond the preview
Go deeper on ChiCTR2200060662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060662.